Your browser doesn't support javascript.
loading
Time from first tumor manifestation to diagnosis in patients with GEP-NET: Results from a large German tertiary referral center.
Koch, Christine; Koca, Esra; Filmann, Natalie; Husmann, Gabriele; Bojunga, Jörg.
Afiliação
  • Koch C; Goethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.
  • Koca E; Goethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.
  • Filmann N; Goethe University Frankfurt, Department of Biostatistics and Mathematical Modeling, Frankfurt, Germany.
  • Husmann G; Goethe University Frankfurt, University Hospital, University Cancer Center, Tumor Documentation, Frankfurt, Germany.
  • Bojunga J; Goethe University Frankfurt, University Hospital, Department of Gastroenterology, Hepatology and Endocrinology, Frankfurt, Germany.
Medicine (Baltimore) ; 100(37): e27276, 2021 Sep 17.
Article em En | MEDLINE | ID: mdl-34664885
ABSTRACT
ABSTRACT Patients with neuroendocrine tumors (NET) often go through a long phase between onset of symptoms and initial diagnosis.Assessment of time to diagnosis and pre-clinical pathway in patients with gastroenteropancreatic NET (GEP-NET) with regard to metastases and symptoms.Retrospective analysis of patients with GEP-NET at a tertiary referral center from 1984 to 2019; inclusion criteria Patients ≥18 years, diagnosis of GEP-NET; statistical analysis using non-parametrical methods.Four hundred eighty-six patients with 488 tumors were identified; median age at first diagnosis (478/486, 8 unknown) was 59 years; 52.9% male patients. Pancreatic NET 143/488 tumors; 29.3%; small intestinal NET 145/488 tumors, 29.7%. 128/303 patients (42.2%) showed NET specific and 122/486 (25%) patients other tumor-specific symptoms. 222/279 patients had distant metastases at initial diagnosis (187/222 liver metastases). 154/488 (31.6%) of GEP-NET were incidental findings. Median time from tumor manifestation (e.g., symptoms related to NET) to initial diagnosis across all entities was 19.5 (95% CI 12-28) days. No significant difference in patients with or without distant metastases (median 73 vs 105 days, P = .42).A large proportion of GEP-NET are incidental findings and only about half of all patients are symptomatic at the time of diagnosis. We did not find a significant influence of the presence of metastases on time to diagnosis, which shows a large variability with a median of <30 days.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Neoplasias Gástricas / Fatores de Tempo / Tumores Neuroendócrinos / Neoplasias Intestinais Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Neoplasias Gástricas / Fatores de Tempo / Tumores Neuroendócrinos / Neoplasias Intestinais Tipo de estudo: Diagnostic_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Medicine (Baltimore) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha